Prospective, Multicenter, Randomized Controlled Clinical Study Evaluating the VitaFlow Liberty® Flex Transcatheter Aortic Valve Delivery System for the Treatment of Severe Aortic Stenosis Lesions

NARecruitingINTERVENTIONAL
Enrollment

232

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2027

Conditions
Aortic Valve Stenosis
Interventions
DEVICE

Transcatheter Aortic Valve Replacement

Transcatheter Aortic Valve Implantation/Replacement (TAVI/TAVR) has gradually emerged as a new treatment option for patients with severe aortic stenosis who are ineligible for open-heart valve replacement or at high surgical risk.

Trial Locations (1)

200032

RECRUITING

180 Fenglin Road, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER

collaborator

First Hospital of China Medical University

OTHER

collaborator

The Affiliated Hospital of Qingdao University

OTHER

collaborator

First Affiliated Hospital of Fujian Medical University

OTHER

collaborator

Renmin Hospital of Wuhan University

OTHER

collaborator

The First Affiliated Hospital of Nanchang University

OTHER

collaborator

The Second Affiliated Hospital of Dalian Medical University

OTHER

collaborator

Guangdong Provincial People's Hospital

OTHER

collaborator

General Hospital of Ningxia Medical University

OTHER

collaborator

Sichuan Provincial People's Hospital

OTHER

collaborator

Second Affiliated Hospital of Nanchang University

OTHER

collaborator

Tang-Du Hospital

OTHER

NCT07145463 - Prospective, Multicenter, Randomized Controlled Clinical Study Evaluating the VitaFlow Liberty® Flex Transcatheter Aortic Valve Delivery System for the Treatment of Severe Aortic Stenosis Lesions | Biotech Hunter | Biotech Hunter